CCL2 and chronic kidney disease: We therefore hypothesized that inhibiting the QC/isoQC activity would trigger the degradation of CCL2 in vivo and inhibit monocyte and macrophage infiltration and inflammation in the kidney, leading to beneficial effects against CKD.